Prognostic Biomarkers are the type of biomarkers that track the progression of a disease with or without treatment. They assess the aggressiveness of the disease and calculate the risk of recurrence or median survival for particular type of malignancy. According to an article published in Journal of Clinical and Cellular Immunology, the field of biomarkers has expanded dramatically in the last 5-6 years with the advancement in high throughput technologies such as mass spectroscopy, genomic and proteomic arrays, sequencing, and many more. Intensifying research in this field can be seen from the increase in the number of publications for novel prognostic biomarkers especially in the field of cancer. A new research presented at Association for the Study of Diabetes (EASD) 2016 Annual Meeting suggests the combination of prognostic biomarkers which could be helpful in noninvasive screening for pancreatic carcinoma in patients with new-onset diabetes. According to an article published in Ebiomedicine, recently researchers have identified 788 potential biomarkers in blood that could be used to develop an early stage carcinoma screening test for the general population.
Novel drug efficiency in clinical trials on a certain population is determined using prognostic biomarkers. Hence, prognostic biomarkers have remarkable potential to affect the success rate of clinical trials. They also help in assessing the need and strategy of treatment for specific patients. In the era of personalized medicines and advanced cancer therapeutics, prognostic markers provide the precise selection of treatment for a patient. Thus, helps in reducing the side effects of chemotherapeutic drugs. For the further prediction and development of novel prognostic biomarkers, collaboration of statistical and bioinformatics data is also required.
Request For Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3139
Prognostic Biomarkers Market: Drivers & Restraints
An ideal biomarker should have analytical validity, clinical validity and clinical utility. Hence, fast, accurate and feasible prognostic biomarker will grow the demand of industry. Also, not all the patients respond favorably to drugs so continuous need of prognostic biomarkers is there for regular assessment of the treatment. Furthermore, increased development of prognostic biomarkers will reduce the treatment cost. Increasing awareness among doctors, patients and technicians in the developing countries would help in promoting the growth of market. Insufficient partnership between industry and academia is one of the restraint of the industry. More chances of experimental failure, some ethical issues, huge investment, time consumption, technical and commercial challenges limits further development of prognostic biomarkers.
Prognostic Biomarkers Market: Segmentation
Segmentation by Therapeutic Type
- Diabetes and others
Segmentation by End User
- Research Institutes
- Diagnostic labs
- Pharmaceutical Industry
- Academic Institutions
Segmentation by Application
- Drug discovery and research
- Clinical Trials
- Company Diagnostics
- Treatment Analysis
Prognostic Biomarkers Market: Overview
Currently, clinicians monitor treatment response by means of blood pressure measurements, anti-double-stranded DNA antibody levels, serum complement levels, urinary protein/creatinine ratios, urinary sediment, and surrogates of renal function. Unfortunately, prediction of disease progression is difficult by using these traditional biomarkers because of their little sensitivity and high LN heterogeneity at presentation. Therefore, continuous need of prognostic biomarker increases for effective treatment strategy these days. Prognostic biomarkers also help the pharmaceutical industry to develop more effective drug and reduce the chances of failure. Sensitivity, specificity and cost are some of the factors determining growth of the industry. The market demand of prognostic biomarkers will increase because of the factors like increasing population, increase in number of chronic diseases, increased investment in healthcare and many more.
Long term investments is one of the requirement essential for the novel systems and thus promoting growth of the industry. One of the commercialized prognostic biomarker assay kit is the Oncotype DX which determine the likelihood that breast cancer will come back in a patient after initial treatment. Similar research activity include Komen funded research projects on prognostic biomarkers which have investment of around $ 60 million in over 120 research grants.
Prognostic Biomarkers Market: Region-wise Outlook
North America dominates the global market because of increasing aging population and increasing innovation and technology. According to WHO cancer trends worldwide, North America is at the top followed by Europe. Furthermore, good reimbursement scenario in these countries increase the demand. Asia-pacific region market is expected to grow in the future because of increase in the number of contract research, increasing population and per capita income of people in these countries. Development of novel biomarkers and their increasing use also help in cutting down the healthcare cost thus promoting the growth of the industry.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3139
Prognostic Biomarkers Market: Key Players
Some of the key players in the prognostic biomarkers industry include Roche diagnostics, Qiagen, Johnson and Johnson, GE Healthcare, Siemens Healthcare, Merck & Co. Inc. and many others.